MeSH Browser

MeSH Heading: Sorafenib
Tree Number(s): D02.065.950.681.757; D02.455.426.559.389.703.757; D03.066.515.530.750; D03.383.725.547.530.750
Unique ID: D000077157
RDF Unique Identifier: http://id.nlm.nih.gov/mesh/D000077157
Scope Note: A niacinamide and phenylurea derivative that inhibits multiple intracellular and cell surface kinases thought to be involved in ANGIOGENESIS, including RAF KINASES and VEGF RECEPTORS. It is used in the treatment of advanced RENAL CELL CARCINOMA and HEPATOCELLULAR CARCINOMA, and for treatment of THYROID CARCINOMA refractory to radioactive iodine therapy.
Entry Term(s): 4-(4-(3-(4-Chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxylic acid methyamide-4-methylbenzenesulfonate; BAY 43-9006; BAY 545-9085; BAY-545-9085; BAY-673472; Nexavar; Sorafenib N-Oxide; Sorafenib Tosylate
Pharm Action: Antineoplastic Agents
Protein Kinase Inhibitors
Related Numbers: 5T62Q3B36J; 5XYK65KIGD
CAS Type 1 Name: 2-Pyridinecarboxamide, 4-(4-((((4-chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-
Public MeSH Note: 2019; SORAFENIB was indexed under NIACINAMIDE and PHENYLUREA COMPOUNDS 2014-2018, and under BENZENESULFONATES and PYRIDINES 2003-2013
History Note: 2019 (2003)
Date Established: 2019/01/01
Date of Entry: 2018/07/09
Revision Date: 2020/05/27

Allowable Qualifiers: administration & dosage (AD)

adverse effects (AE)

agonists (AG)

analogs & derivatives (AA)

analysis (AN)

antagonists & inhibitors (AI)

blood (BL)

cerebrospinal fluid (CF)

chemical synthesis (CS)

chemistry (CH)

classification (CL)

economics (EC)

history (HI)

immunology (IM)

isolation & purification (IP)

metabolism (ME)

pharmacokinetics (PK)

pharmacology (PD)

poisoning (PO)

radiation effects (RE)

standards (ST)

supply & distribution (SD)

therapeutic use (TU)

toxicity (TO)

urine (UR)

Sorafenib MeSH Descriptor Data 2025